The article discusses U.S. President Donald Trump's decision to sign a "Right to Try" bill aimed to offer terminal patients access to unapproved or experimental drugs by bypassing the U.S. Food and Drug Administration.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados